Core Viewpoint - The successful launch of the Shenzhou-20 manned spacecraft carrying 48 samples of planarian worms marks a significant milestone in space research, aiming to explore the regenerative capabilities of these organisms in microgravity and radiation environments [1][2]. Group 1: Research and Development - The project titled "Exploration of the Effects and Mechanisms of Microgravity and Radiation on Planarian Regeneration" was approved in 2022, showcasing a commitment to persistent scientific research and innovation [1]. - The research team, with an average age of 29.4 years, emphasizes the importance of detail in experimental success, reflecting a blend of knowledge, ambition, and confidence in technological innovation [1]. Group 2: Collaborative Efforts - The project benefited from a collaborative approach, breaking down disciplinary barriers and involving institutions such as Dalian Maritime University and the Shanghai Institute of Technical Physics, which contributed to overcoming challenges in developing microfluidic systems for planarian chips [2]. - The integration of resources and expertise from various organizations has provided significant momentum to the project, culminating in the successful launch of the planarian samples into space [2]. Group 3: Application and Industry Impact - The return of the planarian samples and the ongoing collection of foundational research data aim to transition scientific findings from theoretical frameworks to practical applications, targeting the health and life sciences industry [2]. - The second National Planarian Biology Symposium held in 2025 focused on topics such as result transformation and the development of the life health industry, indicating a commitment to aligning research with industry needs [2]. - Collaborations with multiple enterprises in Shandong are underway to accelerate the application of scientific achievements, fostering a modern research cycle that integrates research, transformation, and application [2].

Core Insights - Betaini Group has made significant progress in the upstream medical beauty industry chain with the approval of a new product by its strategic investment, Yizheng (Suzhou) Biotechnology Co., Ltd, which holds 15.73% of its shares [1][4] - The approved product, an injectable poly-L-lactic acid filler, is the first of its kind globally to be approved for use in the temporal region, marking a milestone for the company and the industry in China [1][4] Group 1 - The product received a Class III medical device registration certificate from the National Medical Products Administration (NMPA), indicating its compliance with regulatory standards [1] - The filler utilizes proprietary MEDBIOMA® poly-L-lactic acid material and EvolaONE® microsphere technology developed by the company's core team [1][4] Group 2 - Chengdu Yizhen, founded by a team of scientists led by Dr. Zhang Xiaojin, focuses on the clinical transformation of absorbable biomaterials and has previously launched other Class III medical devices [4] - The approval of this core product signifies a strategic move by Betaini to enhance its value chain in skin health through investment and collaboration in the upstream biomaterials sector [4]

Core Insights - Dark Horse Consulting Group (DHCG) has announced the acquisition of Bruder Consulting & Venture Group (BCVG), enhancing its capabilities in the biotherapy sector, particularly in regenerative medicine, orthopedic, wound care, and plastic and reconstructive surgery markets [1][2] - The acquisition aims to accelerate the development and commercialization of biotherapeutic drugs, expanding DHCG's service offerings to include regenerative medicine, tissue repair, and biomaterials [2] - The integration of BCVG into DHCG is expected to enrich the company's expertise and improve its ability to provide comprehensive solutions to research institutions and investors [2] Company Overview - Dark Horse Consulting Group is a global consulting firm established in 2014, with offices in North America, Europe, and Asia-Pacific, focusing on accelerating the development and delivery of cell and gene therapies [3] - DHCG's consulting expertise spans the entire biopharmaceutical value chain, including strategic planning, operational management, quality control, regulatory affairs, manufacturing, modeling and analysis, supply chain management, market entry, and business optimization [3] - The company comprises three business units: DHC, BioTechLogic, and Converge Consulting, with BCVG now operating as a specialized department under DHC [3] Bruder Consulting & Venture Group Overview - Bruder Consulting & Venture Group is a full-service strategic consulting firm specializing in orthopedic, wound care, and plastic and reconstructive surgery markets, with significant expertise in the discovery, development, clinical design, and regulatory approval processes for bioproducts, medical devices, and combination products [4] - The BCVG team has completed over 900 projects for more than 150 companies globally and has led or supported licensing and acquisition transactions valued at over $2 billion [4]

Core Viewpoint - The collaboration between LianKang Biotechnology Group, Wenzhou Medical University National Engineering Research Center, and Wenzhou Ouhai District People's Government aims to enhance research and development in the fields of skin, ophthalmology, and metabolic-related diseases, accelerating strategic implementation processes [1][2] Group 1: Collaboration Details - A tripartite strategic cooperation agreement has been signed to establish the "LianKang-Wenzhou Medical University Translational Medicine Joint Innovation Laboratory" [1] - The collaboration will leverage each party's strengths in research, industry, and policy to conduct comprehensive cooperation from basic research to clinical transformation and industrialization [2] Group 2: Research Focus - The partnership will explore the synergistic mechanisms of epidermal growth factor (EGF) and fibroblast growth factor (FGF) in regulating metabolic homeostasis, improving insulin sensitivity, and promoting tissue repair [1] - New formulations and delivery systems will be developed targeting diseases such as non-alcoholic steatohepatitis (NASH) and asthma, addressing significant unmet clinical needs in these areas [1] Group 3: Strategic Implications - This collaboration is expected to enhance the group's research efficiency and success rates in the biopharmaceutical innovation sector, shortening product development cycles [2] - The partnership will also facilitate the expansion of existing products into more clinical applications, reinforcing the group's competitive edge in the EGF/FGF niche [2] - The board views this collaboration as a key initiative to deepen the "government-university-enterprise" synergy and integrate into national-level innovation platforms, significantly accelerating the development and transformation of cutting-edge innovation pipelines [2]

Core Viewpoint - The strategic partnership between Link Health Biotechnology Group, Wenzhou Medical University National Engineering Research Center, and Wenzhou Ouhai District People's Government aims to enhance research and development in the fields of skin, ophthalmology, and metabolic-related diseases, accelerating the implementation of the company's strategic initiatives [1][2] Group 1 - The collaboration will leverage the strengths of each party in research, industry, and policy to conduct comprehensive cooperation from basic research to clinical translation and industrialization in the application of growth factor drugs in regenerative medicine [1][2] - The partnership will explore the synergistic mechanisms of epidermal growth factor (EGF) and fibroblast growth factor (FGF) in regulating metabolic homeostasis, improving insulin sensitivity, and promoting tissue repair, with the goal of developing new compound formulations and delivery systems for diseases such as non-alcoholic steatohepatitis (NASH) and asthma [1][2] - This collaboration is expected to fill treatment gaps in multiple niche indications and unlock clinical and commercial value in the vast chronic disease market [1] Group 2 - The Wenzhou Medical University National Engineering Research Center is a leading independent entity focused on basic research and new drug development in the field of growth factor drugs, under the leadership of Academician Li Xiaokun from the Chinese Academy of Engineering [2] - The partnership is anticipated to enhance the company's R&D efficiency and success rate in the biopharmaceutical innovation sector, shorten product development cycles, and strengthen competitiveness in the EGF/FGF niche market [2] - The board views this collaboration as a key initiative to deepen the "government-university-enterprise" synergy and integrate into a national-level innovation platform, significantly accelerating the R&D and translation of cutting-edge innovation pipelines [2]

Core Viewpoint - The strategic cooperation agreement signed between LianKang Biotechnology Group, Wenzhou Medical University National Engineering Research Center, and the Ouhai District People's Government aims to enhance the group's research and development pipeline in the fields of skin, ophthalmology, and metabolic-related diseases, accelerating the implementation of its strategic goals [1][2]. Group 1 - The collaboration will leverage the strengths of each party in research, industry, and policy to conduct comprehensive cooperation from basic research to clinical transformation and industrialization in the application of growth factor drugs in regenerative medicine [1][2]. - The parties will explore the synergistic mechanisms of epidermal growth factor (EGF) and fibroblast growth factor (FGF) in regulating metabolic homeostasis, improving insulin sensitivity, and promoting tissue repair, with the aim of developing new compound formulations and delivery systems [1][2]. - This partnership is expected to fill treatment gaps in various specific indications and further unlock clinical and commercial value in the extensive chronic disease market [1]. Group 2 - The Wenzhou Medical University National Engineering Research Center, led by Academician Li Xiaokun of the Chinese Academy of Engineering, is a leading independent entity in the field of growth factor drugs, focusing on basic research and new drug development [2]. - The Ouhai District People's Government plays a crucial role in supporting this strategic cooperation, aiming to create a top-tier biopharmaceutical industry ecosystem, providing comprehensive support and policy backing for the collaboration project [2]. - This cooperation is anticipated to enhance the group's research efficiency and success rate in the field of biopharmaceutical innovation, shorten product development cycles, and strengthen its competitive edge in the EGF/FGF segment [2].

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 佈 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或 任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 UNI-BIO SCIENCE GROUP LIMITED 聯 康 生 物 科 技 集 團 有 限 公 司* （於開曼群島註冊成立之有限公司） （股份代號：0690） 自願性公佈 聯康集團與溫醫大國家工程研究中心及 溫州市甌海區人民政府達成戰略合作 香港，二零二五年十二月三十日 — 聯康生物科技集團有限公司（「本公司」），連 同其附屬公司統稱（「本集團」）董事會（「董事會」）欣然宣佈，於近日在浙江省溫州 市，本集團與溫州醫科大學細胞生長因子藥物和蛋白製劑國家工程研究中心（「溫 醫 大 國 家 工 程 研 究 中 心 」）及 溫 州 市 甌 海 區 人 民 政 府 正 式 簽 署 三 方 戰 略 合 作 協 議 （「協議」），並就後續共建「聯康 — 溫醫大轉化醫學聯合創新實驗室（」「聯合實驗 室」）事宜進行探討。此次合作有助於強化本集團在皮膚 ...

Core Viewpoint - The establishment of the Regenerative Medicine Clinical Research Center at Hunan University aims to integrate industry, academia, and research to drive innovation in the field of regenerative medicine, focusing on major disease diagnosis and treatment, as well as organ damage repair [1][2]. Group 1: Center Establishment and Objectives - The center is a collaboration involving Hunan University, Hunan Provincial Tumor Hospital, and several other medical institutions, designed to promote a new path for the integration of research and industry [1]. - The center will leverage clinical needs to guide research and innovation, aiming to create a closed loop from basic research to clinical application and industrial transformation [2]. Group 2: Industry Context and Market Potential - The global cell therapy market has surpassed $400 billion, indicating significant growth potential in the regenerative medicine sector [2]. - Hunan Province is working to develop a trillion-level stem cell and regenerative medicine industry chain, with a focus on innovation and collaboration among various stakeholders [2]. Group 3: Strategic Contributions and Infrastructure - Dajia Weikang, as a co-builder of the center, will invest in technology, talent, and funding to accelerate the transition of cutting-edge therapies from the lab to clinical practice [1]. - The center will establish a cell seed bank and regenerative medicine product library, aiming to create an internationally competitive application testing center for stem cells and regenerative medicine products [2].

Core Insights - The establishment of the Boao Lecheng International Medical Tourism Pilot Zone marks a significant milestone in China's medical innovation and policy experimentation, particularly in the context of the Hainan Free Trade Port's opening [1][3] Group 1: Policy and Development - The Boao Lecheng Pilot Zone is recognized as China's only "medical special zone," leveraging four key policy advantages: licensed medical practices, research, operations, and international exchanges, which are driving substantial development effects [3] - The zone has facilitated the approval of 21 international advanced medical devices and 16 special medical foods for clinical use, along with the successful implementation of 16 biomedical new technologies [3] - The goal is to synchronize medical technology, equipment, and pharmaceuticals with international standards by 2025, aiming for over 520 international innovative medical devices to undergo clinical applications in China for the first time [3] Group 2: Clinical Innovations and Expert Discussions - The conference emphasized the importance of establishing clinical guidelines and technical standards to support the implementation of new technologies, particularly in regenerative medicine and real-world data research [5] - Experts highlighted the need for the committee to focus on standard-setting, technology assessment, and industry collaboration to facilitate the standardized application of clinical new technologies [5] - The committee aims to leverage its expertise in cutting-edge fields like stem cells and xenotransplantation to contribute to industry standards and policy discussions [5] Group 3: Future Directions and Strategic Initiatives - The committee's future work will focus on three main areas: ensuring compliance with industry regulations, promoting integration of new technologies with clinical practices and policies, and enhancing international collaboration [7] - Specific initiatives include establishing a Clinical New Technology Application Transformation Center and a Digital Medical Trading Center, as well as launching projects to support reproductive health policies [7][9] - The collaboration between the China Hospital Association and the Boao Lecheng Pilot Zone is expected to accelerate the integration of international medical resources into the Chinese market, fostering high-level development in healthcare [9]

Group 1 - The implementation of the "Regulations on the Management of Clinical Research and Clinical Translation Applications of New Biomedical Technologies" has brought "cell therapy" and "cell drugs" into public life, shaping the future of the life and health industry [1] - The establishment of the Regenerative Medicine Clinical Research Center at Hunan University aims to integrate advantages from industry, academia, research, and medicine, focusing on major disease diagnosis and treatment, as well as tissue and organ damage repair [1] - The center will drive research through clinical needs and empower the industry with expertise, creating a new path for the integration of research and industry, leading to high-quality development in the regenerative medicine sector [1] Group 2 - The global cell therapy market has surpassed $400 billion, and Hunan Province is working to build a trillion-yuan-level stem cell and regenerative medicine industry chain [2] - The center will focus on breakthroughs in key core technologies and establish a comprehensive stem cell traceability system, including a cell seed bank and a regenerative medicine product library [2] - The center aims to produce high-quality innovative results in talent cultivation, technology development, clinical trials, and application promotion in the field of regenerative medicine, contributing to the high-quality development of the biopharmaceutical industry [2] Group 3 - The Dajia Weikang Regenerative Medicine Research Institute is a significant strategic layout in the life and health field, committing to accelerate the transition of cutting-edge therapies from the laboratory to clinical practice [2] - Dajia Weikang has established a GMP-compliant cell bank and laboratory, creating a complete industry chain from cell collection, storage, preparation to application, enhancing the safety and effectiveness of products [2] - The goal is to ensure that the public feels confident and capable of using cell therapy products [2]